Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
12 nov. 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...
ChemoCentryx to Participate in Two Upcoming Investor Conferences
10 nov. 2021 08h00 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two...
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
09 nov. 2021 16h05 HE
|
ChemoCentryx, Inc.
-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan;...
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
04 nov. 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of...
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
02 nov. 2021 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market...
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
11 oct. 2021 08h30 HE
|
ChemoCentryx, Inc.
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI),...
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
08 oct. 2021 07h00 HE
|
ChemoCentryx, Inc.
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif., Oct. 08, 2021 (GLOBE...
ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis
27 sept. 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of...
ChemoCentryx to Participate in Two Upcoming Investor Conferences
02 sept. 2021 08h30 HE
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in...
ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights
09 août 2021 16h05 HE
|
ChemoCentryx, Inc.
-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021-- -- Applications for regulatory approval of avacopan...